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Background: The genetic polymorphism of thiopurine methyltransferase (TPMT) is well characterized in most
populations. Four common polymorphic alleles are associated with impaired activity of the enzyme. These are
TPMT*2 (238G>C), TPMT*3B (c.460G>A), TPMT*3A (c.460G>A and c.719A>G) and TPMT*3C (c.719A>G). The aim of
the present study was to determine the frequency of TPMT polymorphisms and their association with the
occurrence of adverse events, during 6-mercaptopurine therapy in pediatric acute lymphoblastic leukemic (ALL)
patients in Gaza Strip.
Methods: A total of 56 DNA samples from all pediatric ALL patients admitted to the pediatric hematology
departments of Gaza strip hospitals were analyzed. Genomic DNA from peripheral blood leukocytes was isolated
and the TPMT*2, TPMT*3B TPMT*3A and TPMT*3C allelic polymorphism was determined by PCR-RFLP and allele
specific PCR technique.
Results: No TPMT*2, *3B or *3C alleles were detected. Only one, out of 56 patients, was found heterozygous for the
TPMT*3A allele. Thus, the frequency of TPMT*3A allele was calculated to be 0.89%. Fourteen patients of ALL were
suffering from myelotoxicity during 6-MP therapy. From our results, no significant association could be established
between clinical and laboratory data and/or the presence of the mutation in TPMT gene.
Conclusion: TPMT*3A was the only deficiency allele detected in our population with an allelic frequency of 0.89%.
Other polymorphic alleles in TPMT gene, or factors other than TPMT polymorphisms may be responsible for the
development of myelosuppression in cases that don’t carry the investigated TPMT alleles (*2, *3A, *3B and *3C).
Therefore, more studies are recommended to study such factors.
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Thiopurine drugs have been widely used for the treat-
ment of leukemia, autoimmune diseases and organ
transplants. Oral 6-mercaptopurine (6-MP) is routinely
used in maintenance treatment of acute lymphoblastic
leukemia in children, which contributes to the high cure
rates achieved [1,2]. Both 6-Mercaptopurine is a pro-
drug that requires activation by hypoxanthine-guanine
phosphoribosyl transferase (HGPRT) to exert a cyto-
toxic effect [2]. Alternatively, this agent can undergo* Correspondence: bm.ayesh@alaqsa.edu.ps
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reproduction in any medium, provided the orS-methylation catalyzed by thiopurine methyltrans-
ferase (TPMT) to 6-methylmercaptopurine (6-MeMP)
or oxidation to thiouric acid via xanthine oxidase [3].
Metabolism via either TPMT or xanthine oxidase re-
duces formation of the active thioguanine nucleotides.
TPMT enzyme activity is largely influenced by polymor-
phisms in the TPMTgene. People heterozygous for TPMT
mutations have intermediate activity while those homozy-
gous for the mutation have low activity [4]. Over 23 vari-
ants of the TPMT gene are associated with decreased
TPMT activity [5]. Three variant alleles, TPMT*2
(c.238G>C), TPMT*3A (c.460G>A and c.719A>G) and
TPMT*3C (c.719A>G) account for 80–95% of intermedi-
ate or low activity cases [6].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and therapeutic efficacy of thiopurine drugs. Approxi-
mately 1 in 300 have low activity, 6-11% have intermediate
activity and 89-94% have high activity [7-9].
TPMT is encoded by a 34 kb gene consisting of 10
exons and nine introns and has been localized to chromo-
some 6p22.3 [10].
According to the Palestinian Ministry of health hospital
records, in Gaza Strip, the total number of recorded child-
hood ALL patients in 2006 was 15 patients, 14 patients in
2007, 15 patients in 2008 and 12 patients by August, 2009.
6-Mercaptopurine is administered for all patients at one
stage or another of their treatment protocols.
No data are available about the state of TPMT allelic
variation in Gaza neither testing of TPMT polymorph-
ism is carried out. Therefore, this study was conducted.
Methods
Patients and sample collection
This is a descriptive study with Convenience sampling
and definite time period. Fifty six children suffering from
and being managed for acute lymphoblastic leukemia in
European Gaza hospital, AL-Nasser hospital and Abd El
Aziz Al Rantisi hospital were included in the period be-
tween July 2008 to august 2009. The study population
included all patients attending these hospitals at time
of the study. Other types of leukemia were excluded.
Approximately 2.5 ml venous blood samples were col-
lected, from the patients in EDTA tubes.
The procedures of the study were approved by the
Helsinki research ethics committee of the Palestinian au-
thority ministry of health according to the World Medical
Association Declaration of Helsinki [11], and a written
consent was obtained from the parents of each patient.
TPMT genotyping
DNA was extracted from 300 μl whole blood samples
using a commercial kit (promega, USA), according to
the manufacture recommendations, and based on
nonorganic extraction procedure. The extracted DNA
was resuspended in 100 μl of the provided alkaline hy-
dration solution at 65°C.
A total of 56 DNA samples were analyzed. Total gen-
omic DNA extracted from peripheral leucocytes was
processed by PCR either immediately or stored at −20°C
until being used.
An allele-specific PCR [12] was used to analyze the
mutation c.238G>C in exon 5 (TPMT *2 allele), using
sequence specific primers (wild type specific: 5′-GTA
TGA TTT TAT GCA GGT TTG-3′, mutant specific:
5′- GTA TGA TTT TAT GCA GGT TTC-3′ and com-
mon: 5′-TAA ATA GGA ACC ATC GGA CAC-3′) in
two separate 20 μl reactions containing 0.5 μM of each
primer, 5 μl DNA 1X PCR master mix (promega, USA).The cycling conditions consisted 35 cycles of 94°C for
30 s, 53°C for 30 s, and 72°C for 30 s.
The mutations c.719A>G in exon 10 and c.460G>A in
exon 7 (TPMT*3A, TPMT*3B and TPMT*3C alleles) were
determined by polymerase-chain reaction-restriction frag-
ment length polymorphism analysis (PCR-RFLP) using
AccI and MwoI respectively (New England Biolabs, USA)
[12]. The PCR amplifications were carried out in 20 μl
final volume containing 0.5 μM of the primers (5′-AAG
TGT TGG GAT TAC AGG TG-3′ and 5′-TCC TCA
AAA ACA TGT CAG TGT G-3′ for c.719A>G; and 5′-
GGG ACG CTG CTC ATC TTC T-3′ and 5′-GCC TTA
CAC CCA GGT CTC TG-3′ for c.460G>A), 5 μl DNA
and 1X of PCR master mix (promega, USA). The cycling
conditions consisted of 35 cycles of 94°C for 1 min, 56°C
for 1 min, 72°C for 1 min for c.719A>G; and 35 cycles
of 94°C for 1min, 59°C for 1 min, 72°C for 1 min for
c.460G>A.
Data collection and analysis
Relevant medical information was collected from the pa-
tient’s records in the hospitals. Data included adverse ef-
fects such as leucopoenia (white blood cells count <3000/
cubic millimeter), thrombocytopenia (platelets < 100000/
cubic millimeter), abnormal liver function (elevation of
ALT level of 2 or more times the upper limit of normal);
and duration of 6-MP therapy at time of sampling and at
the time of adverse effects appearance. Data were ana-
lyzed using the SPSS software (Version. 17) as needed. Chi
square test and One-Way ANOVA were used and
P-values of < 0.05 were considered statistically significant.
Means were presented ± standard deviation.
Results
Description of the study population
In this study, the sample included 56 pediatric patients
suffering from ALL; 32 (57.1%) were males and 24
(42.9%) were females. Their ages at the time of diagnosis
varied between 6 months to 12 years (mean 4.4 ± 2.6
years). The majority of patients were between 3.7 - 5.1
years with 95% Confidence interval. All patients were di-
agnosed as ALL patients by blood film, bone marrow as-
piration and complete blood cell count (CBC).
In the present study the calculated incidence of ALL
among children in Gaza strip during the specified period
of samples collection was 2 patients per 100000 children.
The incidence of ALL is higher in males than in females.
Management of patients
During the collection of the sample, most of the pa-
tients (75%) were given 6-MP for different periods of
time and 25% of them finished having the 6-MP
treatment.
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the time of the sample collection, 6 patients suffered
from leucopoenia (white blood cells count <3000/cubic
millimeter); 5 patients from leucopoenia and thrombocy-
topenia; 3 patients from leucopoenia , thrombocytopenia
and liver toxicity and 3 patients had only liver toxicity.
When such complications took place, the only interven-
tion was 6-MP dose reduction. During the course of
management, one patient had neuroblastoma and one
patient had mild brain atrophy, which likely didn’t result
from the 6-MP treatment. Bone marrow transplanta-
tion was performed for 2 patients besides the 6-MP
treatment.
TPMT genotypes
The TPMT*2 allele (c.238G>C). TPMT*3B allele
(c.460G>A) and TPMT*C allele (c.719A>G) were not
detected in the studied patients, while one patient was
heterozygous for the TPMT*3A allele (both c.460G>A
and c.719A>G) with allelic frequency of 0.89% (Table 1).
Adverse effects
Collectively, 14 patients developed side effects associated
with 6-MP therapy, characterized by rapidly developing
severe myelosuppression expressed as leucopoenia alone
or in combination with thrombocytopenia. Thirteen of
those patients had wild type TPMT alleles and only one
patient had a heterozygous TPMT*3A genotype.
The duration of 6-MP treatment doesn’t seem to sig-
nificantly correlate with the occurrence of adverse effects
by the time of sample collection (p-value = 0.87).
For the 14 patients with side effects, myelosuppression
occurred at different time periods, ranging from 1–20
months after 6-MP administration (mean= 4.6 ± 5.2
months). On the other hand 6-MP treatment continued
for 1–24 months (mean = 8.6 ±6.2) before samples were
collected from the other patients and yet no evidence of
myelosuppression was detected.
Discussion
TPMT genotype influences the safety and efficacy of
ALL treatment and genotype information may therefore
be useful for optimizing 6-MP therapy [9,13,14]. Patients
with both intermediate and absent TPMT activity haveTable 1 Frequencies of TPMT alleles in 56 samples of Gaza pe
Allele SNP Amino acid sub
TPMT*1 Wild-Type -
TPMT*2 c.238G>C Ala>Pro
TPMT*3A c.460G>A, c.719A>G Ala>Thr, Tyr> Cy
TPMT*3B c.460G>A Ala>Thr
TPMT*3C c.719A>G Tyr> Cys
Total - -an increased risk of developing thiopurine-induced
myelosuppression, compared with patients with normal
activity [15]. For this reason, knowledge of the TPMT
Single Nucleotide Polymorphism frequencies in a popu-
lation is essential for estimating the proportions of risk
groups under 6-MP therapy. From this point of view, in
the current study, the frequencies of four variant TPMT
alleles (TPMT*2, TPMT*3B, TPMT*3C, TPMT*3A), ac-
counting for 80–95% of intermediate or low activity
cases worldwide, were determined in pediatric ALL pa-
tients in Gaza Strip.
Only the TPMT*3A allele was detected in one patient
out of 56 DNA samples from pediatric ALL patients.
The frequency of TPMT*3A allele in Gaza strip is thus
0.89%. No TPMT*2, *3B or *3C alleles were detected.
TPMT*3A allele frequency is consistent with ethnically
related Israeli Arab subpopulations (0.79%) [16]. The fre-
quency of TPMT*3A allele is also similar in Jordanian
population (0.59) [17], Turkish population (0.9%) [18],
and Iranian population (0.87%) [19]. It is lower than that
reported for several Caucasian, African descendants and
South American [17].
In the present study 14 patients developed myelo-
toxicity and they all had a normal TPMT genotype
except for one patient who had the heterozygous
TPMT*3A allele with rapidly developing severe mye-
losuppression. It is noteworthy to mention that not all
cases of myelosupression are due to a mutation in the
gene coding for the TPMT enzyme and therefore, not all
cases can be prevented by screening for TPMT with ei-
ther the enzymatic assay or genotype test [20]. The pres-
ence of toxicity in a number of cases and the lack of
common types of mutations may result from the exist-
ence of other alleles, multigeneic contribution or other
nongenetic factors [21]. Measurement of active 6-MP
metabolite concentrations was suggested to be a key tool
complementary to genotype in predicting toxicity under
treatment with thiopurines [3].
In Gaza pediatric hospitals ALL patients are treated
according to Berlin-Frankfurt-Mu¨nster protocol 2002
(BFM). Moreover protocols for treatment with 6-MP in
local hospitals usually involve initial administration of
low doses followed by gradual increase, but no TPMT or
other metabolizing enzymes investigation are performed.diatric patient with ALL
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TPMT*3A was the only deficiency alleles detected in the
pediatric ALL patients in Gaza strip with an allelic fre-
quency of 0.89%. Cases of myelosuppression in ALL
pediatric patients treated with 6-MP in Gaza strip can-
not be all explained by the existence of TPMT alleles (*2,
*3A, *3B and *3C). Other polymorphic alleles in TPMT
gene, or factors other than TPMT polymorphisms may
be responsible for the development of toxicity.
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